<DOC>
	<DOC>NCT01532570</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650 in patients with Behcet's disease ( BD ) with special lesions after the administration of TA-650 at a dosage of 5 mg/kg in weeks 0, 2, and 6, then every 8 weeks after week 14 up to week 46.</brief_summary>
	<brief_title>Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>Patients who were diagnosed with the complete or incomplete type of Behcet's disease according to "The criteria for a diagnosis of Behcet's disease, Ministry of Health, Labour and Welfare in Japan (partially revised in 2010)" Patients who have special lesions despite having received conventional treatments for special lesions, or patients who cannot receive conventional treatments due to intolerability. Patients who have clinical symptoms associated with each special lesions. Patients with intestinal, neuro, vascular Behcet's disease in whom a differential diagnosis of each Behcet's disease from other conditionsï¼Ž Patients who have received treatment with infliximab within 1 year before enrollment for another purpose than treating special lesions; or patients whose previous treatment with infliximab was discontinued due to adverse events. Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving acquirement.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Behcet's disease</keyword>
	<keyword>intestinal Behcet's disease</keyword>
	<keyword>neuro-Behcet's disease</keyword>
	<keyword>vascular Behcet's disease</keyword>
</DOC>